{"name":"Cycle Pharmaceuticals Ltd.","slug":"cycle-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Orfadin","genericName":"Orfadin","slug":"orfadin","indication":"Homogentisate 1,2dioxygenase deficiency","status":"marketed"}]}],"pipeline":[{"name":"Orfadin","genericName":"Orfadin","slug":"orfadin","phase":"marketed","mechanism":"4-hydroxyphenylpyruvate dioxygenase, 4-hydroxyphenylpyruvate dioxygenase","indications":["Homogentisate 1,2dioxygenase deficiency","Tyrosinemia type I"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSVo2S2NrejZMeWpvQ0tGZnhDVmFmRlVfbVVQWUx2MkZ3NjdSOUtteUk5aDBFODB2X01Ja2hxYzByOVBIVTVXOGkxdVV4alRMZ0pRUFI3UlpvLU5ZMm9vZ1o2MnRrVmo5TnpsT3h2Z0x1SmJPc3pnbmRFMGFlMUE0ekh2RmpPLURZVUhyb0pueG90bkhQOTlZdmZOZUw1OG5icDNzQmQyYkU5a2V4dU5DQjlzZmhGSzFCdXZMSWNkaEUxUQ?oc=5","date":"2026-02-03","type":"pipeline","source":"businesswire.com","summary":"Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics - businesswire.com","headline":"Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWFVRNTZqbnMyN1hnZEhEaHFDR2Nvb3Ntd20xaUppVWJkdS1nVXE4VUxVRTFkSC1WcVdsbU5RQ0gwZjZZdjlodG5XZGVSOUVYVkVHWVNNTlJSeTRLNEdlU2tNRDBpUnQ5bkZzTWI1YVBsbWVERXlXR0VWTkhaNXFpZUxNeWxVNHA0cEZ1MHIxc2ZwOGtKTW1vQXRBVQ?oc=5","date":"2026-01-30","type":"pipeline","source":"Yahoo Finance","summary":"Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer - Yahoo Finance","headline":"Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNZXY2UkJoek51d0xWUUh6Rm5lSWNkWW43VExzWTFieVFPQ1dTODlvQ0E2eVdldEpob3R6OXp3LWlZWEV5cTY1M3IwNC05Y0dyX2I1NFExd2JtZ3dNbGdQbkFLUU5RN3JwMkFRMkJNVTdNVHUyeVhGdDZ3YzFUdkhVR0FQd1Y2bmtjNHFiVUZneEdEbFl4VEZpUHRfR3dSbW1zT3kxbjR3?oc=5","date":"2026-01-16","type":"pipeline","source":"The Times","summary":"Cycle Pharmaceuticals - The Times","headline":"Cycle Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcTlISk1GTlFoUE1zYUJ4X1ZjdHg5bEY4NjBDU1BSenpySGQxTkk4VWNRYktlS19pbl91ZHRlRWE0dXVabGZCUDFEMGFxck9MLUY2WlUtMmNkdTBETFNSb05mTEhXclBJMXpRNWJObGNzWVhFTGVUQ0l6STd2WTRLMHZHTWF5VVRvYndHZTA5OXI1b2xZUmxGUFJ3d3hIUms4azdZWlRsTGF2UkV4Y2ROdVB2bkNZQVRaMVhSY1g2aUVxZFU?oc=5","date":"2025-12-11","type":"deal","source":"GlobeNewswire","summary":"Cycle Pharmaceuticals to Acquire Applied Therapeutics - GlobeNewswire","headline":"Cycle Pharmaceuticals to Acquire Applied Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNnRqWmtFVmRRUXl6T0JienR0dzItbXlqd2RFSTdIMVBUdDNoZDYxNUQ2MkhPc1ZQZExxbzdEU1JSQ3luUnZnVFRlVmxDODc1aEd0UFRBbHBjYzV3YzJSTFAzX1ZKa2tiT29OeEJ1YkNFemhlSG8zVzYzb3ZONE5jMWxJS05LZ2MzRzdxalN4Zmd1cXRGQUhLZnNuQQ?oc=5","date":"2025-12-11","type":"earnings","source":"Stock Titan","summary":"Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026 - Stock Titan","headline":"Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOV2hwWlFPVzQwcTR6aWRvUWpkNU5KRDYtamZYMDM4bDJYNjdvbk1LbTF5WVdXRlc1SmlyRkt0aWlqQzVaR2lEWTJuZ3hVZHdnUVU3bnd3TjU3dlI1ZEllV3V2TS1LdHpSUndZcURMbkVJd1VCRkt0ZWw4SzFCeDlKNUlOMVRMNlJseE9UYVFSajJqaTc3eERCMkJoSGxDcGphV01ZOVQ2eVM5cHdvUDJMckQweVBvTndrbFNRc2ZPSENIUDdTUk9UYldFM1MyZ1JBSGpRcnJOZWtkWjltUF8wWXA2NS0?oc=5","date":"2025-10-16","type":"pipeline","source":"businesswire.com","summary":"Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US - businesswire.com","headline":"Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPYW9WOWJvNW9LZVZrRkZDMF9Rdm12UmF6THpEZU5fR1hENVd4M09KQk5EeFR2dXBILUFBbmY4czUwVDllaUtlb2lmVmhja1gzMmdleGFTNmswY0ZPTzB5aGdRVGlDV0hZaVk0N2Q2Sjl1T1YzalpQWE9DMTJMRUticTAySXJZRnlyYjhXNnJJZFpCMVBrYzJWRHZyOWc1OUFWZ1BtRkEtbDFMcDZVbThlLWh5WlVaZWREcW5Ob1puWlhVUHM?oc=5","date":"2025-07-22","type":"deal","source":"BioSpace","summary":"Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets - BioSpace","headline":"Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-22","type":"regulatory","source":"BioSpace","summary":"Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Partner for HARLIKU™ (nitisinone) Tablets — the First and only FDA-approved Treatm","headline":"Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Pa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNOTFMbFg2SjVIUGIyQkhxOTNXNTFib0FCU1JFRU9lSzlBRjRhQ1ZKZUxyZWtfUTBEWkVidnBiRU1aUEZaZG12Z25jWjFjVHhBUTVhZmVfRW5vV0VFcmE4UUhLRE1PWGo2Q0JUQTZtWVN3NE43dU5GcmE3a2RtS3lnNUd5OFR5R1BMVmFuZHkyWTF6c0thSVhBbVFoZ0wyUlhqeG1VUk91SDNzOVR6T1pwQkpXd0NvNTI0ZHctdlFyQS1qYVdjbHBubHEzNi02NXlZV1dYM2NXQ2YtR2s1UVpTdE03c1A0SVlwNW1GNGcyV0JmTE4xazg1Mmt3?oc=5","date":"2025-06-19","type":"regulatory","source":"businesswire.com","summary":"Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU) - businesswire.com","headline":"Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOVVlZUUtWU0tLdXd6MkQzU0R1TU5lbmNtOGYwVjJRWWxqbU5Cd1dBcjUzUldMR3d4NlhRTzNxZ2czUWVLcTUycVhmV3U0a2lqSHZ6cXBZLTFLcXZCa3NpMkJOekVYRjNhUk5iall5cTNDVjJuTVdva093TEdFa1loWjgwbkhxbXNWZUVyaFhVSlBSRWVLRmp6Q2l2M2NvZmZTR0hpRjBmMUNDU1FzaHo3alJDVEstWWlxNlQ3LU54ZEJaYUZ6YllaSjE2Y18?oc=5","date":"2025-01-14","type":"pipeline","source":"Investors in Healthcare","summary":"UK: Cycle Pharmaceuticals completes acquisition of Banner Life Sciences - Investors in Healthcare","headline":"UK: Cycle Pharmaceuticals completes acquisition of Banner Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQTS01bUxwb2dsUjlUeUlxMDg0LTRVaXlMTFkyeXk5UDFVYUZwTk9XbVctYTdaUmJhQW1WU1VMd1pUNl9NUnhBNWwxMWV5Nms2bXBPUnNFcHc3eklRMjdxS0lWVkhfaTMwcmpEVGN6SFNWUEV6RFZhZVhBV3FFbnhIa0pLc0J0NGs2OFlhN1E4bEhENE1iQ2pzYWdoVU5Sdm1jM20zS2dzSVk1WjBYQVE?oc=5","date":"2024-10-14","type":"pipeline","source":"Reuters","summary":"Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters","headline":"Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQTXBDMVBncUwySkhGWGFFaTh1WUpORmlQMkkzOUZseWZHSzdUX1Z4Zm5maG9zZXktVmFaOHdjcnhCYTMtbjZtNHFzWkItcTlMcXhHMWttVHNoM2Zvam5mV1YtNzduWXFqdWRtUHJYRlk1emg2ZmlKcXdxNHFqeEV0T1NYcUQyeTNjVlRoZTMwY1NCeW41M3ZyeXlWRG5Dam45dnQ3a2c2enZOcEh2U3ZiN1pQVURlVUd3cTdscloxYmRnSFdwQkdEUENaSmJpNWR3ZTEtNFk2VVdxVXVWZ1NlNlBfS0lJOFE2WENVcmRCOWtXU2N6cVdDYmxCVVRxcnRDZjBzYg?oc=5","date":"2024-06-06","type":"pipeline","source":"prnewswire.com","summary":"Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. - prnewswire.com","headline":"Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}